From real to regulatory: why RWD needs trial-grade standards
As the US Food and Drug Administration (FDA) becomes more receptive to the use of real-world data (RWD) in drug…
Interviews
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved
FDA’s latest CGT guidance streamlines path for in vivo CAR-T development
Animal testing alternatives to dominate, but not overnight
Walgreens sets sights on clinical trial network growth in recruitment drive
FDA genAI reviews hinge on clarity of dossiers
Synthetic control arms: full impact yet to be realised
Are DCTs truly more sustainable?
